Dupilumab in Moderate-to-Severe Atopic Dermatitis With or Without Comorbid Food Allergy: Pooled Analysis of 2 Randomized Phase 3 Trials (LIBERTY AD SOLO 1 & 2)
Endpoints included proportion of patients with Investigator’s Global Assessment (IGA) 0/1, >=75% improvement in Eczema Area and Severity Index (EASI-75), and peak pruritus Numerical Rating Scale (NRS) improvement >=4. Conclusions This post-hoc subgroup analysis shows that dupilumab-treated pat...
Saved in:
Published in | Journal of allergy and clinical immunology Vol. 141; no. 2; p. AB131 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
St. Louis
Elsevier Inc
01.02.2018
Elsevier Limited |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Endpoints included proportion of patients with Investigator’s Global Assessment (IGA) 0/1, >=75% improvement in Eczema Area and Severity Index (EASI-75), and peak pruritus Numerical Rating Scale (NRS) improvement >=4. Conclusions This post-hoc subgroup analysis shows that dupilumab-treated patients with and without patient-reported comorbid FA have comparable/significant improvement in AD signs and symptoms. |
---|---|
ISSN: | 0091-6749 1097-6825 |
DOI: | 10.1016/j.jaci.2017.12.418 |